By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Bristol Myers Squibb Co. forecast 2025 sales and profit below Wall Street’s expectations — a sign that declining sales of ...

The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 billion, according to LSEG data. It forecast 2025 earnings in the ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

By age 75, a noteworthy 50% of men develop an inguinal (groin) hernia. Although common, the cause of these hernias is unknown, and the only treatment is surgery to repair the weakened area. Even after ...

About 800,000 Americans will have a heart attack or stroke this year. While heart disease can affect anyone, the risk substantially rises with age.

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...